Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How a Physician Practice Can Be Ready for a Pediatric Medical Emergency

Do you see pediatric patients, or do children often accompany adults to visits at your practice or medical office? Then you very likely will encounter a serious pediatric illness or injury requiring a medical emergency response. Managing a pediatric medical emergency is not the same as treating an adult—types of emergencies and responses can vary in…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Do you see pediatric patients, or do children often accompany adults to visits at your practice or medical office? Then you very likely will encounter a serious pediatric illness or injury requiring a medical emergency response.

Managing a pediatric medical emergency is not the same as treating an adult—types of emergencies and responses can vary in specific ways with younger patients. Physician practices must know the differences and be prepared.

Differences between Pediatric, Adult Emergencies

While children experience many of the same common medical emergencies as adults, there are critical differences including higher rates of shock and dehydration, respiratory distress, seizures, infection, and serious trauma among younger patients. One reason: some parents choose to bring a child with a developing health issue to their family doctor rather than the emergency room.

Basic Requirements: A Plan and Child-Specific Supplies

Medical response to children largely follows the protocols—and uses much the same equipment—as for adults. Here are the basic requirements recommended by the American Academy of Pediatrics.

Primarily because they are smaller than adults, children can need medical responses using specialized supplies and administration.

  • For airway and resuscitation Pediatric-sized IV gauges Separate infant and pediatric bag-valve-masks and face masks. While a manually triggered oxygen resuscitator is a positive pressure option for administration to adults, it can deliver an overwhelming tidal volume to pediatric patients and smaller adults. Use a portable cylinder with a child-sized oxygen bag-valve-mask instead.
  • For allergic reactions: Pediatric-dose epinephrine auto injector. (If a pedi auto-injector isn’t available, use an adult auto-injector as last resort.)
  • For medication dosing, use the Broselow tape as a reference. This worldwide-accepted medical aide was developed by noted pediatric emergency care physician Dr. James Broselow, a member of the Banyan Medical Advisory Board.

Developing a Preparedness Plan

In addition to appropriate supplies, make sure you have an appropriate plan of action. The first step is to perform a self-assessment of readiness to respond to the most common medical emergencies. The resulting plans should include procurement and organization of equipment and medications to maintain a child until the arrival of emergency services. The plan also should include a maintenance and replenishment process for the supplies.

Incorporate the STAT KIT® Pedi

Banyan offers a comprehensive way to equip a practice for a pediatric medical emergency. We have collaborated with Dr. Broselow to develop the STAT KIT® Pedi. The kit is organized into three levels, with specific attention to efficient organization of the equipment and medications needed for a pediatric emergency. See a video tour here.

OnTraq Keeps Your Kit Current

The STAT KIT® Pedi includes the OnTraq Medications and Supplies Replenishmentprogram. This free service tracks the expiration dates of emergency medications and supplies in your emergency medical kit or crash cart and prompts replacement shipments prior to their expiration.

About Banyan

Since 1971, Banyan has provided STAT KITs that are trusted by physicians in a range of specialties. We are registered with the FDA, DEA and have Verified-Accredited Wholesale Distribution accreditation from the National Boards of Pharmacy. Consult with a Banyan readiness advisor today by calling 888-782-8548 or emailing us.

Read more at statkit.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512